Creating Hope Reauthorization Act of 2024

House Bill 7384 - Creating Hope Reauthorization Act of 2024: Overview, Status, and Impact

Hozzl · 2024-03-14T04:05:40Z

Explore the details of House Bill 7384 Creating Hope Reauthorization Act of 2024 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

3/14/2024, 4:05 AM

Congressional Summary of HR 7384

Creating Hope Reauthorization Act of 2024

This bill extends until FY2029 a Food and Drug Administration program that awards priority review vouchers to manufacturers of drugs that treat rare pediatric diseases. (A priority review voucher entitles the voucher holder to priority review of a single human drug application.)

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 7384

Bill HR 7384 is currently in the status of Bill Introduced since February 15, 2024. Bill HR 7384 was introduced during Congress 118 and was introduced to the House on February 15, 2024. Bill HR 7384's most recent activity was Referred to the House Committee on Energy and Commerce. as of February 15, 2024

Bipartisan Support of Bill HR 7384

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 7384

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 7384

Creating Hope Reauthorization Act of 2024

To amend the Federal Food, Drug, and Cosmetic Act to extend the authority of the Secretary of Health and Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases.